CONTEXT: People with prediabetes are at high risk of developing diabetes. OBJECTIVE: The objective of this study was to determine the pathogenesis of fasting and postprandial hyperglycemia in prediabetes. DESIGN: Glucose production, gluconeogenesis, glycogenolysis, and glucose disappearance were measured before and during a hyperinsulinemic clamp using [6,6-(2)H2]glucose and the deuterated water method corrected for transaldolase exchange. SETTING: The study was conducted at the Mayo Clinic Clinical Research Unit. PARTICIPANTS: Subjects with impaired fasting glucose (IFG)/normal glucose tolerance (NGT) (n = 14), IFG/impaired glucose tolerance (IGT) (n = 18), and normal fasting glucose (NFG)/NGT (n = 16) were studied. INTERVENTION: A hyperinsulinemic clamp was used. OUTCOME MEASURES: Glucose production, glucose disappearance, gluconeogenesis, and glycogenolysis were measured. RESULTS: Fasting glucose production was higher (P < .0001) in subjects with IFG/NGT than in those with NFG/NGT because of increased rates of gluconeogenesis (P = .003). On the other hand, insulin-induced suppression of glucose production, gluconeogenesis, glycogenolysis, and stimulation of glucose disappearance all were normal. Although fasting glucose production also was increased (P = .0002) in subjects with IFG/IGT, insulin-induced suppression of glucose production, gluconeogenesis, and glycogenolysis and stimulation of glucose disappearance were impaired (P = .005). CONCLUSIONS: Fasting hyperglycemia is due to excessive glucose production in people with either IFG/NGT or IFG/IGT. Both insulin action and postprandial glucose concentrations are normal in IFG/NGT but abnormal in IFG/IGT. This finding suggests that hepatic and extrahepatic insulin resistance causes or exacerbates postprandial glucose intolerance in IFG/IGT. Elevated gluconeogenesis in the fasting state in IFG/NGT and impaired insulin-induced suppression of both gluconeogenesis and glycogenolysis in IFG/IGT suggest that alteration in the regulation of these pathways occurs early in the evolution of type 2 diabetes.
CONTEXT: People with prediabetes are at high risk of developing diabetes. OBJECTIVE: The objective of this study was to determine the pathogenesis of fasting and postprandial hyperglycemia in prediabetes. DESIGN:Glucose production, gluconeogenesis, glycogenolysis, and glucose disappearance were measured before and during a hyperinsulinemic clamp using [6,6-(2)H2]glucose and the deuterated water method corrected for transaldolase exchange. SETTING: The study was conducted at the Mayo Clinic Clinical Research Unit. PARTICIPANTS: Subjects with impaired fasting glucose (IFG)/normal glucose tolerance (NGT) (n = 14), IFG/impaired glucose tolerance (IGT) (n = 18), and normal fasting glucose (NFG)/NGT (n = 16) were studied. INTERVENTION: A hyperinsulinemic clamp was used. OUTCOME MEASURES: Glucose production, glucose disappearance, gluconeogenesis, and glycogenolysis were measured. RESULTS: Fasting glucose production was higher (P < .0001) in subjects with IFG/NGT than in those with NFG/NGT because of increased rates of gluconeogenesis (P = .003). On the other hand, insulin-induced suppression of glucose production, gluconeogenesis, glycogenolysis, and stimulation of glucose disappearance all were normal. Although fasting glucose production also was increased (P = .0002) in subjects with IFG/IGT, insulin-induced suppression of glucose production, gluconeogenesis, and glycogenolysis and stimulation of glucose disappearance were impaired (P = .005). CONCLUSIONS: Fasting hyperglycemia is due to excessive glucose production in people with either IFG/NGT or IFG/IGT. Both insulin action and postprandial glucose concentrations are normal in IFG/NGT but abnormal in IFG/IGT. This finding suggests that hepatic and extrahepatic insulin resistance causes or exacerbates postprandial glucose intolerance in IFG/IGT. Elevated gluconeogenesis in the fasting state in IFG/NGT and impaired insulin-induced suppression of both gluconeogenesis and glycogenolysis in IFG/IGT suggest that alteration in the regulation of these pathways occurs early in the evolution of type 2 diabetes.
Authors: E Ferrannini; A Gastaldelli; Y Miyazaki; M Matsuda; M Pettiti; A Natali; A Mari; R A DeFronzo Journal: Diabetologia Date: 2003-07-23 Impact factor: 10.122
Authors: Blaire E Burman; Peter Bacchetti; Claudia E Ayala; Nicholas Gelman; Jennifer Melgar; Mandana Khalili Journal: Liver Int Date: 2014-09-20 Impact factor: 5.828
Authors: Hana Alkhalidy; Will Moore; Aihua Wang; Jing Luo; Ryan P McMillan; Yao Wang; Wei Zhen; Matthew W Hulver; Dongmin Liu Journal: J Nutr Biochem Date: 2018-05-01 Impact factor: 6.048
Authors: Stephanie T Chung; Amber B Courville; Anthony U Onuzuruike; Mirella Galvan-De La Cruz; Lilian S Mabundo; Christopher W DuBose; Kannan Kasturi; Hongyi Cai; Ahmed M Gharib; Peter J Walter; H Martin Garraffo; Shaji Chacko; Morey W Haymond; Anne E Sumner Journal: JCI Insight Date: 2018-09-20
Authors: Ron T Varghese; Chiara Dalla Man; Anu Sharma; Ivan Viegas; Cristina Barosa; Catia Marques; Meera Shah; John M Miles; Robert A Rizza; John G Jones; Claudio Cobelli; Adrian Vella Journal: J Clin Endocrinol Metab Date: 2016-09-07 Impact factor: 5.958
Authors: Tamara S Hannon; M S Kirkman; Yash R Patel; Robert V Considine; Kieren J Mather Journal: Diabetes Metab Res Rev Date: 2014-11 Impact factor: 4.876
Authors: Santhosh Satapati; Blanka Kucejova; Joao A G Duarte; Justin A Fletcher; Lacy Reynolds; Nishanth E Sunny; Tianteng He; L Arya Nair; Kenneth A Livingston; Kenneth Livingston; Xiaorong Fu; Matthew E Merritt; A Dean Sherry; Craig R Malloy; John M Shelton; Jennifer Lambert; Elizabeth J Parks; Ian Corbin; Mark A Magnuson; Jeffrey D Browning; Shawn C Burgess Journal: J Clin Invest Date: 2015-11-16 Impact factor: 14.808